Status:
RECRUITING
Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Lymphomas
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Lymphomas are the most common haemopathic malignancy. The 3 most common types are diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL) and follicular lymphoma (FL). In these three subtypes, ...
Eligibility Criteria
Inclusion
- Person who has not opposed to their inclusion in the trial
- Confirmation of the diagnosis of one of the lymphomas (DGLBL, LF, classic LH, LT or LCM) according to the WHO 2016 international classification (Smerdlow et al, 2016)
- Patients not currently taking treatment for their haemopathy (or who have received corticosteroid therapy alone within 14 days prior to the 1st sampling, dose limited to 500mg total)
- Patients requiring systemic treatment within 30 days of screening
Exclusion
- Person subject to legal protection (curatorship, guardianship)
- Person under partial judicial control
- Pregnant, parturient or breastfeeding woman
- Adult incapable or incapable to express his or her non-opposition
- Minor
- Localized lymphoma treated by surgery and/or localized radiotherapy
Key Trial Info
Start Date :
May 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2046
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04417803
Start Date
May 17 2021
End Date
May 1 2046
Last Update
June 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourgogne
Dijon, France, 21000